130 related articles for article (PubMed ID: 33512867)
1. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
[TBL] [Abstract][Full Text] [Related]
2. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
3. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
Israel EN; Thomas CA; Mastropietro CW
Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
6. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children.
Greene LA; Law C; Jung M; Walton S; Ignjatovic V; Monagle P; Raffini LJ
J Thromb Haemost; 2014 Sep; 12(9):1554-7. PubMed ID: 24943261
[TBL] [Abstract][Full Text] [Related]
7. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
[TBL] [Abstract][Full Text] [Related]
8. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
9. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
[TBL] [Abstract][Full Text] [Related]
10. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
11. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
13. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.
Ho SH; Wu JK; Hamilton DP; Dix DB; Wadsworth LD
J Pediatr Hematol Oncol; 2004 Sep; 26(9):561-6. PubMed ID: 15342982
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin in thrombotic disease in children and adolescents.
Punzalan RC; Hillery CA; Montgomery RR; Scott CA; Gill JC
J Pediatr Hematol Oncol; 2000; 22(2):137-42. PubMed ID: 10779027
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
Massicotte P; Adams M; Marzinotto V; Brooker LA; Andrew M
J Pediatr; 1996 Mar; 128(3):313-8. PubMed ID: 8774496
[TBL] [Abstract][Full Text] [Related]
16. Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
Andrade-Campos MM; Montes-Limón AE; Fernandez-Mosteirin N; Salvador-Osuna C; Torres M; Lucia-Cuesta JF; Rubio-Felix D
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):194-8. PubMed ID: 23358201
[TBL] [Abstract][Full Text] [Related]
17. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
18. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
[TBL] [Abstract][Full Text] [Related]
20. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.
Celik F; Huitema AD; Hooijberg JH; van de Laar AW; Brandjes DP; Gerdes VE
Obes Surg; 2015 Apr; 25(4):628-34. PubMed ID: 25223871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]